Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Engrailed-1 induces long-lasting behavior benefit in an experimental Parkinson primate model.

Thomasson N, Pioli E, Friedel C, Monseur A, Lavaur J, Moya KL, Bezard E, Bousseau A, Prochiantz A.

Mov Disord. 2019 Jul;34(7):1082-1084. doi: 10.1002/mds.27714. Epub 2019 May 11. No abstract available.

PMID:
31077447
2.

Extracting Geometric Structures in Images with Delaunay Point Processes.

Favreau JD, Lafarge F, Bousseau A, Auvolat A.

IEEE Trans Pattern Anal Mach Intell. 2019 Jan 1. doi: 10.1109/TPAMI.2018.2890586. [Epub ahead of print]

PMID:
30605093
3.

Nosocomial outbreak of Pseudomonas aeruginosa associated with a drinking water fountain.

Costa D, Bousseau A, Thevenot S, Dufour X, Laland C, Burucoa C, Castel O.

J Hosp Infect. 2015 Nov;91(3):271-4. doi: 10.1016/j.jhin.2015.07.010. Epub 2015 Aug 17.

PMID:
26341271
4.

Pyrosequencing analysis of bacterial diversity in dental unit waterlines.

Costa D, Mercier A, Gravouil K, Lesobre J, Delafont V, Bousseau A, Verdon J, Imbert C.

Water Res. 2015 Sep 15;81:223-31. doi: 10.1016/j.watres.2015.05.065. Epub 2015 Jun 3.

PMID:
26072020
5.

Are dentists enough aware of infectious risk associated with dental unit waterlines ?

Robert A, Bousseau A, Costa D, Barbot V, Imbert C.

Bull Group Int Rech Sci Stomatol Odontol. 2013 Jul 10;52(1):e29-34.

PMID:
25461446
6.

Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure.

Ayraud-Thévenot S, Huart C, Mimoz O, Taouqi M, Laland C, Bousseau A, Castel O.

J Hosp Infect. 2012 Dec;82(4):290-2. doi: 10.1016/j.jhin.2012.08.016. Epub 2012 Oct 24.

PMID:
23102815
7.

Rich Intrinsic Image Decomposition of Outdoor Scenes from Multiple Views.

Laffont PY, Bousseau A, Drettakis G.

IEEE Trans Vis Comput Graph. 2013 Feb;19(2):210-24. doi: 10.1109/TVCG.2012.112. Epub 2012 Apr 17.

PMID:
22508899
8.

Real-time rendering of rough refraction.

de Rousiers C, Bousseau A, Subr K, Holzschuch N, Ramamoorthi R.

IEEE Trans Vis Comput Graph. 2012 Oct;18(10):1591-1602.

PMID:
22144527
9.

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.

Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM.

Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485. Review.

10.

[Prevention of fungal infections related to the water supply in French hospitals: proposal for standardization of methods].

Kauffmann-Lacroix C, Bousseau A, Dalle F, Brenier-Pinchart MP, Delhaes L, Machouart M, Gari-Toussaint M, Datry A, Lacroix C, Hennequin C, Toubas D, Morin O.

Presse Med. 2008 May;37(5 Pt 1):751-9. doi: 10.1016/j.lpm.2007.09.015. Epub 2008 Feb 20. French.

PMID:
18243636
11.

Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423.

De Bolle L, Andrei G, Snoeck R, Zhang Y, Van Lommel A, Otto M, Bousseau A, Roy C, De Clercq E, Naesens L.

Biochem Pharmacol. 2004 Jan 15;67(2):325-36.

PMID:
14698045
12.

Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs.

Evers M, Barrière JC, Bashiardes G, Bousseau A, Carry JC, Dereu N, Filoche B, Henin Y, Sablé S, Vuilhorgne M, Mignani S.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9.

PMID:
14643337
13.

2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections.

Snoeck R, Andrei G, Bodaghi B, Lagneaux L, Daelemans D, de Clercq E, Neyts J, Schols D, Naesens L, Michelson S, Bron D, Otto MJ, Bousseau A, Nemecek C, Roy C.

Antiviral Res. 2002 Sep;55(3):413-24.

PMID:
12206879
14.

A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

Druillennec S, Dong CZ, Escaich S, Gresh N, Bousseau A, Roques BP, Fournié-Zaluski MC.

Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4886-91.

15.

Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry.

Soler F, Poujade C, Evers M, Carry JC, Hénin Y, Bousseau A, Huet T, Pauwels R, De Clercq E, Mayaux JF, Le Pecq JB, Dereu N.

J Med Chem. 1996 Mar 1;39(5):1069-83.

PMID:
8676342
16.

Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action.

Evers M, Poujade C, Soler F, Ribeill Y, James C, Lelièvre Y, Gueguen JC, Reisdorf D, Morize I, Pauwels R, De Clercq E, Hénin Y, Bousseau A, Mayaux JF, Le Pecq JB, Dereu N.

J Med Chem. 1996 Mar 1;39(5):1056-68.

PMID:
8676341
17.

Polyanion inhibitors of human immunodeficiency virus and other viruses. 1. Polymerized anionic surfactants.

Leydet A, Barthelemy P, Boyer B, Lamaty G, Roque JP, Bousseau A, Evers M, Hénin Y, Snoeck R, Andrei G, et al.

J Med Chem. 1995 Jun 23;38(13):2433-40.

PMID:
7608908
18.

Prevention of HIV coat protein (gp120) toxicity in cortical cell cultures by riluzole.

Sindou P, Couratier P, Esclaire F, Yardin C, Bousseau A, Hugon J.

J Neurol Sci. 1994 Nov;126(2):133-7.

PMID:
7853017
19.
20.
21.

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.

Mayaux JF, Bousseau A, Pauwels R, Huet T, Hénin Y, Dereu N, Evers M, Soler F, Poujade C, De Clercq E, et al.

Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3564-8.

23.

Radioprotective effects of the immunostimulating lauroylpeptide LtriP (RP 56142).

Migliore-Samour D, Bousseau A, Caillaud JM, Naussac A, Sedqi M, Ferradini C, Jollès P.

Experientia. 1993 Feb 15;49(2):160-6.

PMID:
8440352
24.

RP 54745, a potential antirheumatic compound. II. In vivo properties in different animal models.

Folliard F, Bousseau A, Terlain B.

Agents Actions. 1992 May;36(1-2):127-35.

PMID:
1414681
25.

RP 54745, a potential antirheumatic compound. I. Inhibitor of macrophage stimulation and interleukin-1 production.

Folliard F, Bousseau A, Terlain B.

Agents Actions. 1992 May;36(1-2):119-26.

PMID:
1414680
26.

An exon 5-deleted mRNA encodes a functional interleukin 2 receptor alpha-subunit.

Mercken L, Moras V, Hemon L, Lionne B, Bousseau A, Dautry-Varsat A, Collins M, Mayaux JF.

Biochem Biophys Res Commun. 1991 Nov 14;180(3):1390-5.

PMID:
1840490
27.

Acute effects of tumor necrosis factor on the microcirculation in rat cremaster muscle.

Vicaut E, Hou X, Payen D, Bousseau A, Tedgui A.

J Clin Invest. 1991 May;87(5):1537-40.

28.
29.

Amoeboid Microglial Cells and not Astrocytes Synthesize TNF-alpha in Swiss Mouse Brain Cell Cultures.

Hetier E, Ayala J, Bousseau A, Denèfle P, Prochiantz A.

Eur J Neurosci. 1990;2(9):762-768.

PMID:
12106276
30.

[Cachectin or TNF (tumor necrosis factor): clinical implications].

Romieu M, Riche F, Bousseau A, Szekeli B, Schurando P, Briard C, Payen D.

Ann Fr Anesth Reanim. 1990;9(6):525-35. Review. French.

PMID:
2278419
31.

RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release.

Floch A, Bousseau A, Hetier E, Floc'h F, Bost PE, Cavero I.

J Lipid Mediat. 1989 Nov-Dec;1(6):349-60.

PMID:
2519903
32.

[Plasma concentration of tumor necrosis factor correlated with gravity of septic shock].

Romieu M, Bousseau A, Riche F, Payen D.

Ann Fr Anesth Reanim. 1989;8 Suppl:R238. French. No abstract available.

PMID:
2604196
33.

Brain macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro.

Hetier E, Ayala J, Denèfle P, Bousseau A, Rouget P, Mallat M, Prochiantz A.

J Neurosci Res. 1988 Oct-Dec;21(2-4):391-7.

PMID:
3265161

Supplemental Content

Loading ...
Support Center